A day to make a difference

Giving Tuesday is a time to celebrate our community. Until December 2, every donation will be multiplied 4X thanks to a generous legacy match from Judy Hazlett’s estate. Your gift drives vital Parkinson’s research, expands access to peer mentors and support groups, and helps people across Canada put life back into living. Give today and multiply your impact for the Parkinson’s community.

Give today and 4X your impact

Community updates

George keeps on playing

George has always been a musician. He plays guitar, drums, and teaches music. In 2018, Parkinson's changed the tempo of his life, but he still marches on to his own beat.

Read his story >>

The questions you asked in 2025

This year, you had a ton of questions about living with Parkinson’s. From medications to caregiving, here’s what you asked most and what we learned together.

Take a look >>

What you need to know

Our webpage provides an overview of what it is like to live with Parkinson's in Canada: from diagnosis and the costs involved, to what we still need to learn.

Learn the reality >>

December webinar

Discover new ways to move, feel, and live better with Parkinson’s! Join us on Wednesday, December 10, from 2–3 p.m. ET for an inspiring and interactive wellness webinar. You’ll meet three Parkinson Canada CARE Fund recipients who are transforming care through innovative programs.

The future of Parkinson’s treatment

While current treatments manage symptoms, they don’t slow the progression of Parkinson's. Disease-modifying therapies (DMTs) aim to change that by targeting the underlying causes of Parkinson’s: from harmful protein buildup to gene changes and cell loss. Researchers are exploring new antibody drugs, gene and stem cell therapies, and even repurposed medications that could slow progression and improve quality of life. As this research advances, it’s vital that our community understands what these therapies mean and how they could shape care in the years ahead.

Learn more about DMT for Parkinson’s

Blog supported by Roche.